Simultaneously, treatment with PP2 significantly reduced nuclear PKM2 levels, suppressing the transcription of its downstream target genes (such as GLUT1, LDHA, and MYC) and markedly weakening tumor cells’ glycolytic capacity and proliferative ability [30]. The gene discussed is SLC2A1; the disease is neoplasm.